Sun Pharmaceutical Industries Limited (BOM:524715)
India · Delayed Price · Currency is INR 1,989.35
-11.40 (-0.57%)
At close: Jul 31, 2026
BOM:524715 Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 599,105 | 584,620 | 525,784 | 484,969 | 438,857 | 386,545 |
Revenue Growth | 11.40% | 11.19% | 8.42% | 10.51% | 13.53% | 15.39% |
Gross Profit Gross Profit Growth | 472,835 | 459,834 | 410,200 | 370,547 | 325,670 | 277,784 |
Operating Income Operating Income Growth | 137,965 | 136,116 | 126,055 | 105,202 | 93,058 | 81,560 |
Net Income Net Income Growth | 120,956 | 114,794 | 109,290 | 95,764 | 84,736 | 32,727 |
Earnings Per Share EPS Growth | 50.40 | 47.80 | 45.55 | 39.90 | 35.30 | 13.60 |
EPS Growth | 16.54% | 4.94% | 14.16% | 13.03% | 159.56% | 12.40% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
India Formulations India Formulations Growth | 200,442 | 192,904 | 169,230 | 148,893 | 136,031 | 127,593 |
US Formulations US Formulations Growth | 168,209 | 168,242 | 162,403 | 153,493 | 135,353 | 113,737 |
Emerging Markets Emerging Markets Growth | 115,790 | 111,865 | 94,160 | 86,195 | 78,977 | 67,432 |
Rest of the World Formulations Rest of the World Formulations Growth | 87,634 | 85,684 | 71,626 | 67,128 | 60,426 | 54,545 |
Active Pharmaceutical Ingredients (API) Active Pharmaceutical Ingredients (API) Growth | 22,421 | 21,853 | 21,292 | 19,187 | 19,724 | 18,354 |
Other Segment Other Segment Growth | 1,680 | 1,654 | 1,702 | 2,690 | 2,279 | 2,604 |
Other Operating Other Operating Growth | 2,929 | 2,419 | 5,372 | 7,384 | 6,068 | 2,281 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 335,166 | 335,166 | 261,227 | 190,901 | 151,300 | 126,548 |
Total Debt Total Debt Growth | 46,273 | 46,273 | 23,622 | 32,737 | 68,859 | 12,903 |
Net Cash (Debt) Net Cash Growth | 288,893 | 288,893 | 237,605 | 158,164 | 82,441 | 113,645 |
Net Cash Growth | 21.58% | 21.58% | 50.23% | 91.85% | -27.46% | 99.57% |
Net Cash Per Share Net Cash Per Share Growth | 120.48 | 120.41 | 99.03 | 65.92 | 34.36 | 47.37 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | 124,192 | 140,721 | 121,350 | 49,593 | 89,845 |
Capital Expenditures CapEx Growth | - | -36,094 | -21,286 | -22,018 | -20,856 | -14,950 |
Free Cash Flow Free Cash Flow Growth | - | 88,098 | 119,435 | 99,332 | 28,738 | 74,895 |
Free Cash Flow Growth | - | -26.24% | 20.24% | 245.65% | -61.63% | 49.78% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 78.92% | 78.66% | 78.02% | 76.41% | 74.21% | 71.86% |
Operating Margin | 23.03% | 23.28% | 23.97% | 21.69% | 21.20% | 21.10% |
Pretax Margin | 26.69% | 25.77% | 26.13% | 22.78% | 21.33% | 11.55% |
Profit Margin | 20.19% | 19.64% | 20.79% | 19.75% | 19.31% | 8.47% |
FCF Margin | - | 15.07% | 22.72% | 20.48% | 6.55% | 19.38% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 16.000 | 16.000 | 16.000 | 13.500 | 11.500 | 10.000 |
Dividend Per Share Growth | 0% | 0% | 18.52% | 17.39% | 15.00% | 33.33% |
Dividend Yield | 0.80% | 0.91% | 0.93% | 0.85% | 1.21% | 1.14% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 39.48 | 36.73 | 38.08 | 40.60 | 27.84 | 67.06 |
P/FCF Ratio | 54.21 | 47.86 | 34.85 | 39.14 | 82.08 | 29.30 |
PS Ratio | 7.97 | 7.21 | 7.92 | 8.02 | 5.38 | 5.68 |